StocktoriaAptevo Therapeutics Inc. APVO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $3.1M | $12.3M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M |
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
| Shareholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M |
| Ratios | |||||
| Operating margin | — | — | — | -919.7% | -174.1% |
| Net margin | — | — | — | 257.8% | -231.5% |
| FCF margin | — | — | — | -676.0% | -182.2% |
| Return on assets | -95.5% | -154.8% | -70.1% | 23.5% | -50.3% |
| Return on equity | -149.4% | -507.5% | -142.5% | 44.7% | -2340.2% |
| Debt / equity | — | — | 0.00× | 0.08× | 3.05× |
| Current ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 |
| Revenue growth | — | — | — | -74.7% | 185.3% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001671584 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.